Adenosine deaminase is another biomarker that has been studied on CSF for TBM with a recent meta-analysis of 43 studies and over 5000 patients finding pooled sensitivity of 86% (95% CI, 86–91%) and specificity 89% (95% CI, 86–91%) [36]. The gene discussed is ADA; the disease is meningeal tuberculosis.